1006 related articles for article (PubMed ID: 18579512)
1. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women.
Chae SJ; Kim JJ; Choi YM; Hwang KR; Jee BC; Ku SY; Suh CS; Kim SH; Kim JG; Moon SY
Hum Reprod; 2008 Aug; 23(8):1924-31. PubMed ID: 18579512
[TBL] [Abstract][Full Text] [Related]
2. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
3. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria.
Yilmaz M; Isaoglu U; Delibas IB; Kadanali S
J Obstet Gynaecol Res; 2011 Aug; 37(8):1020-6. PubMed ID: 21481088
[TBL] [Abstract][Full Text] [Related]
4. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
5. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population.
Pehlivanov B; Orbetzova M
Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of insulin resistance and metabolic syndrome in patients with polycystic ovary syndrome.
Lankarani M; Valizadeh N; Heshmat R; Peimani M; Sohrabvand F
Gynecol Endocrinol; 2009 Aug; 25(8):504-7. PubMed ID: 19499403
[TBL] [Abstract][Full Text] [Related]
9. The metabolic syndrome in young Korean women with polycystic ovary syndrome.
Park HR; Choi Y; Lee HJ; Oh JY; Hong YS; Sung YA
Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S243-6. PubMed ID: 17610984
[TBL] [Abstract][Full Text] [Related]
10. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
11. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
12. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
Wan DH; Fan P; Bai H; Song Q; Liu HW
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
[TBL] [Abstract][Full Text] [Related]
13. [Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population].
Kavardzhikova S; Pechlivanov B
Akush Ginekol (Sofiia); 2010; 49(4):32-7. PubMed ID: 20734639
[TBL] [Abstract][Full Text] [Related]
14. Serum leptin levels correlate with clinical and biochemical indices of insulin resistance in women with polycystic ovary syndrome.
Pehlivanov B; Mitkov M
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):153-9. PubMed ID: 19340711
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
[TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women.
Liou TH; Yang JH; Hsieh CH; Lee CY; Hsu CS; Hsu MI
Fertil Steril; 2009 Dec; 92(6):1960-5. PubMed ID: 18980763
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance is not strictly associated with energy intake or dietary macronutrient composition in women with polycystic ovary syndrome.
Toscani MK; Mario FM; Radavelli-Bagatini S; Spritzer PM
Nutr Res; 2011 Feb; 31(2):97-103. PubMed ID: 21419313
[TBL] [Abstract][Full Text] [Related]
18. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome.
Thomann R; Rossinelli N; Keller U; Tirri BF; De Geyter C; Ruiz J; Kränzlin M; Puder JJ
Gynecol Endocrinol; 2008 Apr; 24(4):199-206. PubMed ID: 18382906
[TBL] [Abstract][Full Text] [Related]
19. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
20. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]